Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Igor Gonda
Igor Gonda, South Yarra AU
| Patent application number | Description | Published |
|---|---|---|
| 20100322884 | METHOD AND COMPOSITION FOR TRANSDERMAL DRUG DELIVERY - The invention is directed to a transdermal drug delivery composition which includes at least one physiologically active agent; and at least one volatile solvent; and at least one viscosity modulating agent. The invention extends to methods of administering such a composition to a subject and treatment of subjects using the composition. | 12-23-2010 |
Igor Gonda, San Francisco, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20080264416 | Method of Treating Diabetes Mellitus in a Patient - Dosages of inhaled insulin are controlled within a narrow range by controlling the total volume of air inhaled by a patient. By repeatedly delivering aerosolized insulin with the same total inhaled volume of air, the amount of insulin delivered to the patient each time is consistent. A device for delivering insulin by inhalation is disclosed which device comprises a means for measuring inhaled volume and for halting inhalation at a pre-determined point. The device also comprises an adjustable means for applying various amounts of force to a container of formulation to expel different amounts of drug from the container based on the force applied. | 10-30-2008 |
| 20100209538 | PH-MODULATED FORMULATIONS FOR PULMONARY DELIVERY - An aerosolizable formulation comprised of a drug, a carrier and pH affecting component is disclosed. The drug is dissolved in the formulation at a concentration above which it remains in solution at neutral pH. This increases the concentration of the drug in solution making it possible to administer larger amounts of drug with the same or a smaller volume of formulation. When the formulation is aerosolized to small particles and inhaled into human lungs in small volumes (e.g. 0.05 to 0.5 mL) the fluids in the lungs neutralize the formulation causing the drug to participate out of solution. This results in the drug being delivered at a controlled rate below the rate at which drug is administered from a formulation initially at a neutral pH. | 08-19-2010 |
Igor Gonda, Hayward, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20090004249 | DUAL RELEASE NICOTINE FORMULATIONS, AND SYSTEMS AND METHODS FOR THEIR USE - This invention relates generally to a method to provide habitual tobacco users with products, methods and apparatus to reduce and eventually terminate their dependence on nicotine containing products. More specifically, the invention relates to a nicotine-based medicament that is formulated in such a way as to effectively reduce or eliminate the sensations of craving associated with addictive nicotine use. | 01-01-2009 |
| 20090004250 | DUAL RELEASE NICOTINE FORMULATIONS, AND SYSTEMS AND METHODS FOR THEIR USE - This invention relates generally to a method to provide habitual tobacco users with products, methods and apparatus to reduce and eventually terminate their dependence on nicotine containing products. More specifically, the invention relates to a nicotine-based medicament that is formulated in such a way as to effectively reduce or eliminate the sensations of craving associated with addictive nicotine use. | 01-01-2009 |
| 20090005423 | SYSTEMS AND METHODS FOR EFFECTING CESSATION OF TOBACCO USE - The invention relates generally to a system and method for treating conditions responsive to nicotine therapy. More specifically, the invention relates to pulmonary administration of a nicotine containing formulation to effect smoking cessation. | 01-01-2009 |
| 20090241950 | METHOD OF TREATING DIABETES MELLITUS IN A PATIENT - The need for the delivery of insulin by injection can be reduced or eliminated by delivering an aerosolized monomeric insulin formulation. Repeatability of dosing and more particularly the repeatability of the blood concentration versus time profile is improved relative to regular insulin. The blood concentration versus time profile is substantially unaffected by specific aspects of the patient=s breathing maneuver at delivery. Further, the rate at which blood glucose is lowered is increased by the use of monomeric insulin. Particles of insulin and in particular monomeric insulin delivered to the surface of lung tissue will be absorbed into the circulatory system. The monomeric insulin may be a dry powder but is preferably in a liquid formulation delivered to the patient from a hand-held, self-contained device which automatically releases an aerosolized burst of formulation. The device includes a sensor which is preferably electronic which measures inspiratory flow and volume which measurement can be used to control the point of drug release. | 10-01-2009 |
Igor Gonda, Victoria AU
| Patent application number | Description | Published |
|---|---|---|
| 20080226699 | Method and System for Rapid Transdermal Administration - Invention relates to a method for transdermal delivery of a topically applied physiologically active agent comprising: providing a micro-projection apparatus comprising an array of microprojections ( | 09-18-2008 |